Breast cancer accounted for nearly 20 per cent of all female cancer incidences in China in 2018, according to the World Health Organization. Photo: View Portfolio Breast cancer accounted for nearly 20 per cent of all female cancer incidences in China in 2018, according to the World Health Organization. Photo: View Portfolio
Breast cancer accounted for nearly 20 per cent of all female cancer incidences in China in 2018, according to the World Health Organization. Photo: View Portfolio

Genor Biopharma eyes top position among Chinese firms in breast cancer drugs category with affordable alternatives

  • Shanghai-based Genor Biopharma plans to seek regulatory approval for coprelotamab to be used in China on late-stage breast cancer patients
  • Genor shares debuted at HK$29.20 in Hong Kong on Wednesday, 21.7 per cent higher than its IPO price of HK$24

Topic |   Health & Fitness
Breast cancer accounted for nearly 20 per cent of all female cancer incidences in China in 2018, according to the World Health Organization. Photo: View Portfolio Breast cancer accounted for nearly 20 per cent of all female cancer incidences in China in 2018, according to the World Health Organization. Photo: View Portfolio
Breast cancer accounted for nearly 20 per cent of all female cancer incidences in China in 2018, according to the World Health Organization. Photo: View Portfolio
READ FULL ARTICLE